Summary
Antagonists for the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor may have therapeutic potential as neuroprotectant agents in conditions of neuronal degeneration that include brain ischemia, Huntington's chorea, and Alzheimer's disease. Here we have investigated the pharmacological actions of LY 274614, a structurally novel competitive NMDA receptor antagonist, for pharmacological selectivity and neuroprotectant effects following systemic administration. LY 274614 potently displaced NMDA receptor ([3H]CGS19755) binding (IC50=58.8±10.3 nM), but had no appreciable affinity at [3H]AMPA or [3H]kainate receptor sites at up to 10,000 nM. NMDA-induced convulsions in neonatal rats or NMDA-induced lethality in mice are potently and selectively antagonized by i.p. or p.o. LY 274614. Oral doses showed a delayed but prolonged duration of effect. In adult rats, the neuro-degenerative effects (loss of choline acetyltransferase activity) following the intrastriatal infusions of NMDA or quinolinate, but not kainate, were prevented by LY 274614 (2.5 to 20mg/kg i.p.). LY 274614 is an effective neuroprotectant agent against NMDA receptor-induced toxicity when administered systemically and is a promising therapeutic agent for conditions where glutamate plays a role in the pathology of neuronal degeneration.
Similar content being viewed by others
References
Aebischer B, Frey P, Haerter H-P, Herrling PL, Mueller W, Olverman JH, Watkins JC (1989) Synthesis and NMDA antagonist properties of the enantiomers of 4-(3-phosphonopropyl)piperazine-2-carboxylic acid (CPP) and of the unsaturated analogue (E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CPPene). Helv Chim Acta 72: 1043–1051
Bennet JP Jr (1978) Methods in binding studies. In: Yamamura HI, Enna SJ, Kuhar MJ (eds) Neurotransmitter receptor binding, 1st edn. Raven Press, New York, pp 57–90
Chandra V, Kokmen E, Schoenberg BS, Beard CM (1989) Head trauma with loss of consciousness as a risk for Alzheimer's disease. Neurology 39: 1576–1578
Choi DW (1988) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemie damage. Trends Neurosci 11: 465–469
Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171–182
Collingridge GL, Lester RAJ (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 40: 143–210
Faden AI, Demediuk P, Panter SS, Vink R (1989) The role of excitatory amino acids and NMDA receptors in traumatic brain inury. Science 244: 798–800
Faden AI, Ellison JA, Noble LJ (1990) Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 175: 165–174
Fagg GE, Olpe H-R, Pozza MF, Baud J, Steinmann M, Schmutz M, Portet C, Baumann P, Thedinga K, Bittiger H, Allgeier H, Heckendorn R, Angst C, Brundish D, Dingwall JG (1990) CGP37849 and CGP39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol 99: 791–797
Ferkany JW, Kyle DJ, Willets J, Rzeszotarski WJ, Guzewska ME, Ellenberger SR, Jones SM, Sacaan AI, Snell LD, Borosky S, Jones BE, Johnson KM, Balster RL, Burchett K, Kawasaki K, Hoch DB, Dingledine R (1989) Pharmacological profile of NPC-12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 250: 100–109
Foster AC, Gill R, Woodruff GN (1988) Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J Neurosci 8: 4745–4754
Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10: 593–602
Grudt TJ, Jahr CE (1990) Quisqualate activates N-methyl-D-aspartate receptor channels in hippocampal neurons maintained in culture. Mol Pharmacol 37: 477–481
Leander JD, Lawson RR, Ornstein PL, Zimmermann DM (1988) N-Methyl-D-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res 448: 115–120
Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy De, Steel DJ, Williams M, Cheney DL, Wood PL (1988) CGS19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther 246: 65–75
Lehmann J, Schneider J, McPherson S, Murphy DE, Bernard P, Tsai C, Bennett DA, Pastor G, Steel DJ, Boehm C, Cheney DL, Liebman JM, Williams M, Wood PL (1987) CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characerization in vitro and in vivo. J Pharmacol Exp Ther 240: 737–746
Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 11: 81–86
Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11: 379–387
Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365–402
Murphy DE, Hutchison AJ, Hurt SD, Williams M, Sills MA (1988) Characterization of the binding of [3H]-CGS1977: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br J Pharmacol 95: 932–938
Nielson EO, Madsen U, Schaumburg K, Brehm L, Kroggsgaard-Larsen P (1986) Studies on receptor-active conformations of excitatory amino acid agonists and antagonists. Eur J Med Chem-Chim Ther 21: 433–437
Ornstein PL (1990) Excitatory amino acid receptor antagonists. US patent 4902695
Ornstein PL, Schoepp DD, Leander JD, Wong DT, Zimmerman DM, Lodge D (1990) LY233053: a structurally novel, potent and selective competitive N-methyl-D-aspartate receptor antagonist. In: Meldrum BS, Williams M (eds) Current and future trends in anticonvulsant, anxiety, and stroke therapy. Wiley-Liss, New York, pp 429–433
Randolph LK, Ciminera JL (1975) Statistics. In: Osol A, Hoover JE (eds) Remington's pharmaceutical sciences, 15th edn. Mack Publishing Company, Easton, pp 117–150
Schoepp DD, Azzaro AJ (1983) Effects of intrastriatal kainic acid injection on [3H]dopamine metabolism in rat striatal slices: evidence for postsynaptic glial cell metabolism by both the type A and B forms of monoamine oxidase. J Neurochem 40: 1340–1348
Schoepp DD, Salhoff CR, Hillman CC, Ornstein PL (1989) CGS-19755 and MK-801 selectivity prevent rat striatal cholinergic and GABAergic neuronal degeneration induced by N-methyl-D-aspartate and ibotenate in vivo. J Neural Transm 78: 183–192
Schoepp DD, Gamble AY, Salhoff CR, Johnson BG, Ornstein PL (1990a) Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes. Eur J Pharmacol 182: 421–427
Schoepp DD, Ornstein PL, Leander JD, Lodge D, Salhoff CR, Zeman S, Zimmerman DM (1990b) Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive NMDA antagonist with a short duration of action. J Pharmacol Exp Ther 255: 1301–1308
Simon JR, Contrera JF, Kuhar MJ (1976) Binding of [3H]kainic acid, an analogue of L-glutamate, to brain membranes. J Neurochem 26: 141–147
Watkins JC, Krogsgaard-Larsen P, Honore T (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11: 25–33
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schoepp, D.D., Ornstein, P.L., Salhoff, C.R. et al. Neuroprotectant effects of LY 274614, a structurally novel systemically active competitive NMDA receptor antagonist. J. Neural Transmission 85, 131–143 (1991). https://doi.org/10.1007/BF01244705
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01244705